U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07204249) titled 'Glutide for Ending Methamphetamine' on Sept. 24.
Brief Summary: GEM is a pilot study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD).
This pilot study will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, with a subsequent follow-up visit at week 20. This phase will evaluate the feasibility, acceptability, and preliminary efficacy of Wegovy for MeUD.
Study Start Date: Jan. 15, 2026
Study Type: INTERVENTIONAL
Condition:
Methamphetamine-dependence
Intervention:
DRUG: Semaglutide
Semaglutide
Recruit...